Journal Article
. 2019 Jun;380(25).
doi: 10.1056/NEJMoa1904819.

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer

Joseph A Sparano 1 Robert J Gray 1 Peter M Ravdin 1 Della F Makower 1 Kathleen I Pritchard 1 Kathy S Albain 1 Daniel F Hayes 1 Charles E Geyer 1 Elizabeth C Dees 1 Matthew P Goetz 1 John A Olson 1 Tracy Lively 1 Sunil S Badve 1 Thomas J Saphner 1 Lynne I Wagner 1 Timothy J Whelan 1 Matthew J Ellis 1 Soonmyung Paik 1 William C Wood 1 Maccon M Keane 1 Henry L Gomez Moreno 1 Pavan S Reddy 1 Timothy F Goggins 1 Ingrid A Mayer 1 Adam M Brufsky 1 Deborah L Toppmeyer 1 Virginia G Kaklamani 1 Jeffrey L Berenberg 1 Jeffrey Abrams 1 George W Sledge 1 
Affiliations
  • PMID: 31157962
  •     28 References
  •     45 citations

Abstract

Background: The use of adjuvant chemotherapy in patients with breast cancer may be guided by clinicopathological factors and a score based on a 21-gene assay to determine the risk of recurrence. Whether the level of clinical risk of breast cancer recurrence adds prognostic information to the recurrence score is not known.

Methods: We performed a prospective trial involving 9427 women with hormone-receptor-positive, human epidermal growth factor receptor 2-negative, axillary node-negative breast cancer, in whom an assay of 21 genes had been performed, and we classified the clinical risk of recurrence of breast cancer as low or high on the basis of the tumor size and histologic grade. The effect of clinical risk was evaluated by calculating hazard ratios for distant recurrence with the use of Cox proportional-hazards models. The initial endocrine therapy was tamoxifen alone in the majority of the premenopausal women who were 50 years of age or younger.

Results: The level of clinical risk was prognostic of distant recurrence in women with an intermediate 21-gene recurrence score of 11 to 25 (on a scale of 0 to 100, with higher scores indicating a worse prognosis or a greater potential benefit from chemotherapy) who were randomly assigned to endocrine therapy (hazard ratio for the comparison of high vs. low clinical risk, 2.73; 95% confidence interval [CI], 1.93 to 3.87) or to chemotherapy plus endocrine (chemoendocrine) therapy (hazard ratio, 2.41; 95% CI, 1.66 to 3.48) and in women with a high recurrence score (a score of 26 to 100), all of whom were assigned to chemoendocrine therapy (hazard ratio, 3.17; 95% CI, 1.94 to 5.19). Among women who were 50 years of age or younger who had received endocrine therapy alone, the estimated (±SE) rate of distant recurrence at 9 years was less than 5% (≤1.8±0.9%) with a low recurrence score (a score of 0 to 10), irrespective of clinical risk, and 4.7±1.0% with an intermediate recurrence score and low clinical risk. In this age group, the estimated distant recurrence at 9 years exceeded 10% among women with a high clinical risk and an intermediate recurrence score who received endocrine therapy alone (12.3±2.4%) and among those with a high recurrence score who received chemoendocrine therapy (15.2±3.3%).

Conclusions: Clinical-risk stratification provided prognostic information that, when added to the 21-gene recurrence score, could be used to identify premenopausal women who could benefit from more effective therapy. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00310180.).

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Paul E Goss, James N Ingle, +15 authors, Joseph L Pater.
N Engl J Med, 2003 Oct 11; 349(19). PMID: 14551341
Highly Cited.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Population-based validation of the prognostic model ADJUVANT! for early breast cancer.
Ivo A Olivotto, Chris D Bajdik, +6 authors, Karen A Gelmon.
J Clin Oncol, 2005 Apr 20; 23(12). PMID: 15837986
Highly Cited.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer.
Janice M Walshe, Neelima Denduluri, Sandra M Swain.
J Clin Oncol, 2006 Nov 30; 24(36). PMID: 17130515
Review.
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
Clifford A Hudis, William E Barlow, +8 authors, Jo Anne Zujewski.
J Clin Oncol, 2007 May 22; 25(15). PMID: 17513820
Highly Cited.
Statistics in medicine--reporting of subgroup analyses in clinical trials.
Rui Wang, Stephen W Lagakos, +2 authors, Jeffrey M Drazen.
N Engl J Med, 2007 Nov 23; 357(21). PMID: 18032770
Highly Cited.
Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study.
Lisbeth Bertelsen, Leslie Bernstein, +16 authors, Jonine L Bernstein.
J Natl Cancer Inst, 2007 Dec 27; 100(1). PMID: 18159070
Development of the 21-gene assay and its application in clinical practice and clinical trials.
Joseph A Sparano, Soonmyung Paik.
J Clin Oncol, 2008 Feb 09; 26(5). PMID: 18258979
Highly Cited. Review.
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.
Lori J Goldstein, Robert Gray, +12 authors, Joseph A Sparano.
J Clin Oncol, 2008 Aug 06; 26(25). PMID: 18678838    Free PMC article.
Highly Cited.
Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study.
Stella Mook, Marjanka K Schmidt, +6 authors, Peter M Ravdin.
Lancet Oncol, 2009 Oct 06; 10(11). PMID: 19801202
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.
Sandra M Swain, Jong-Hyeon Jeong, +14 authors, Norman Wolmark.
N Engl J Med, 2010 Jun 04; 362(22). PMID: 20519679    Free PMC article.
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Gong Tang, Steven Shak, +6 authors, Norman Wolmark.
Breast Cancer Res Treat, 2011 Jan 12; 127(1). PMID: 21221771    Free PMC article.
Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.
Chungyeul Kim, Gong Tang, +18 authors, Soonmyung Paik.
J Clin Oncol, 2011 Sep 29; 29(31). PMID: 21947828    Free PMC article.
Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.
Gong Tang, Jack Cuzick, +6 authors, Norman Wolmark.
J Clin Oncol, 2011 Oct 20; 29(33). PMID: 22010013    Free PMC article.
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R Peto, +15 authors, K Pritchard.
Lancet, 2011 Dec 14; 379(9814). PMID: 22152853    Free PMC article.
Highly Cited.
The importance of systemic therapy in minimizing local recurrence after breast-conserving surgery: the NSABP experience.
Eleftherios P Mamounas, Gong Tang, Qing Liu.
J Surg Oncol, 2014 Apr 15; 110(1). PMID: 24729388    Free PMC article.
Review.
Adjuvant ovarian suppression in premenopausal breast cancer.
Prudence A Francis, Meredith M Regan, +28 authors, International Breast Cancer Study Group.
N Engl J Med, 2014 Dec 17; 372(5). PMID: 25495490    Free PMC article.
Highly Cited.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +28 authors, George W Sledge.
N Engl J Med, 2015 Sep 29; 373(21). PMID: 26412349    Free PMC article.
Highly Cited.
Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14.
Norman Wolmark, Eleftherios P Mamounas, +6 authors, Soonmyung Paik.
J Clin Oncol, 2016 May 25; 34(20). PMID: 27217450    Free PMC article.
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
Fatima Cardoso, Laura J van't Veer, +32 authors, MINDACT Investigators.
N Engl J Med, 2016 Aug 25; 375(8). PMID: 27557300
Highly Cited.
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2018 Jun 05; 379(2). PMID: 29860917    Free PMC article.
Highly Cited.
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Prudence A Francis, Olivia Pagani, +34 authors, SOFT and TEXT Investigators and the International Breast Cancer Study Group.
N Engl J Med, 2018 Jun 05; 379(2). PMID: 29863451    Free PMC article.
Highly Cited.
21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer.
Charles E Geyer, Gong Tang, +8 authors, Norman Wolmark.
NPJ Breast Cancer, 2018 Nov 21; 4. PMID: 30456299    Free PMC article.
Estimating Risk of Recurrence for Early Breast Cancer: Integrating Clinical and Genomic Risk.
Mitch Dowsett, Nicholas Turner.
J Clin Oncol, 2019 Feb 12; 37(9). PMID: 30742561
Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
B Fisher, J Dignam, +10 authors, R G Margolese.
J Natl Cancer Inst, 1997 Dec 09; 89(22). PMID: 9390536
Panoptic View of Prognostic Models for Personalized Breast Cancer Management.
Geetanjali Saini, Karuna Mittal, +3 authors, Ritu Aneja.
Cancers (Basel), 2019 Sep 11; 11(9). PMID: 31500225    Free PMC article.
Review.
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.
Joseph A Sparano, Robert J Gray, +26 authors, George W Sledge.
JAMA Oncol, 2019 Oct 01; 6(3). PMID: 31566680    Free PMC article.
Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy.
Salomon M Stemmer, Mariana Steiner, +16 authors, David B Geffen.
NPJ Breast Cancer, 2019 Nov 16; 5. PMID: 31728408    Free PMC article.
Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?
Marie Alexandre, Aurélie Maran-Gonzalez, +6 authors, Séverine Guiu.
Cancer Manag Res, 2019 Dec 19; 11. PMID: 31849525    Free PMC article.
Review.
Clinicopathologic analysis of 722 breast cancer patients who met the inclusion criteria of the TAILORx trial.
Hong-Yu Xiang, Yin-Hua Liu, +7 authors, Qian Liu.
Chin Med J (Engl), 2019 Dec 07; 132(24). PMID: 31809316    Free PMC article.
Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li-Fraumeni syndrome).
Vanessa Petry, Renata Colombo Bonadio, +6 authors, Maria Del Pilar Estevez-Diz.
Fam Cancer, 2019 Nov 22; 19(1). PMID: 31748977
Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer.
Philip D Poorvu, Shari I Gelber, +12 authors, Ann H Partridge.
J Clin Oncol, 2019 Dec 07; 38(7). PMID: 31809240    Free PMC article.
MAGI1, a New Potential Tumor Suppressor Gene in Estrogen Receptor Positive Breast Cancer.
Begoña Alday-Parejo, François Richard, +5 authors, Curzio Rüegg.
Cancers (Basel), 2020 Jan 23; 12(1). PMID: 31963297    Free PMC article.
The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients.
Maj-Britt Jensen, Anne-Vibeke Lænkholm, +9 authors, Bent Ejlertsen.
NPJ Breast Cancer, 2020 Mar 07; 6. PMID: 32140564    Free PMC article.
A new clinical-genomic model to predict 10-year recurrence risk in primary operable breast cancer patients.
Tzu-Ting Huang, Lei Lei, +3 authors, Skye Hung-Chun Cheng.
Sci Rep, 2020 Mar 19; 10(1). PMID: 32184406    Free PMC article.
Decision-making of Adjuvant Chemotherapy for Breast Cancer Patients with Discordant Risk Classifications between Clinical-Pathological Factors and 21-gene Recurrence Score.
Weiqi Gao, Lin Lin, +2 authors, Kunwei Shen.
J Cancer, 2020 Mar 24; 11(9). PMID: 32201521    Free PMC article.
Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.
Ugo Testa, Germana Castelli, Elvira Pelosi.
Med Sci (Basel), 2020 Mar 27; 8(1). PMID: 32210163    Free PMC article.
Review.
Ki-67 index, progesterone receptor expression, histologic grade and tumor size in predicting breast cancer recurrence risk: A consecutive cohort study.
Yanna Zhang, Yidong Zhou, +2 authors, Qiang Sun.
Cancer Commun (Lond), 2020 Apr 16; 40(4). PMID: 32291973    Free PMC article.
Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer.
Jinani Jayasekera, Joseph A Sparano, +5 authors, Jeanne Mandelblatt.
JNCI Cancer Spectr, 2020 Apr 28; 3(4). PMID: 32337487    Free PMC article.
PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer.
Lutfi H Alfarsi, Rokaya El Ansari, +4 authors, Andrew R Green.
BMC Cancer, 2020 May 16; 20(1). PMID: 32410585    Free PMC article.
MST1R (RON) expression is a novel prognostic biomarker for metastatic progression in breast cancer patients.
Brian G Hunt, Christina A Wicker, +3 authors, Susan E Waltz.
Breast Cancer Res Treat, 2020 Apr 29; 181(3). PMID: 32342233    Free PMC article.
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer.
K Almstedt, S Mendoza, +9 authors, M Schmidt.
Breast Cancer Res Treat, 2020 May 22; 182(1). PMID: 32436145    Free PMC article.
Deep learning-based survival prediction for multiple cancer types using histopathology images.
Ellery Wulczyn, David F Steiner, +7 authors, Martin C Stumpe.
PLoS One, 2020 Jun 20; 15(6). PMID: 32555646    Free PMC article.
Distribution of the 21-Gene Breast Recurrence Score in Patients with Primary Breast Cancer in Germany.
Vincent P Walter, Florin-Andrei Taran, +6 authors, Andreas Daniel Hartkopf.
Geburtshilfe Frauenheilkd, 2020 Jun 23; 80(6). PMID: 32565552    Free PMC article.
A novel 4-aminoquinazoline derivative, DHW-208, suppresses the growth of human breast cancer cells by targeting the PI3K/AKT/mTOR pathway.
Shu Wang, Yingshi Zhang, +6 authors, Qingchun Zhao.
Cell Death Dis, 2020 Jul 02; 11(6). PMID: 32606352    Free PMC article.
The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real-world early-stage breast cancer.
Daniel A Goldstein, Chen Mayer, +5 authors, Hadar Goldvaser.
Cancer Med, 2020 May 07; 9(13). PMID: 32372569    Free PMC article.
Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic.
Laura M Spring, Michelle C Specht, +6 authors, Beverly Moy.
N Engl J Med, 2020 Jul 02; 383(3). PMID: 32610007    Free PMC article.
Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer.
Francesca Parisi, Maria Grazia Razeti, +7 authors, Matteo Lambertini.
Clin Med Insights Oncol, 2020 Jul 11; 14. PMID: 32647477    Free PMC article.
Association of Independent Prognostic Factors and Treatment Modality With Survival and Recurrence Outcomes in Breast Cancer.
Dat Nguyen, John Yu, William C Reinhold, Sherry X Yang.
JAMA Netw Open, 2020 Jul 10; 3(7). PMID: 32644137    Free PMC article.
Integrated Analysis of Key Differentially Expressed Genes Identifies DBN1 as a Predictive Marker of Response to Endocrine Therapy in Luminal Breast Cancer.
Lutfi H Alfarsi, Rokaya El Ansari, +5 authors, Andrew R Green.
Cancers (Basel), 2020 Jun 18; 12(6). PMID: 32545448    Free PMC article.
Management of hormone receptor-positive, HER2-negative early breast cancer.
Elaine M Walsh, Karen L Smith, Vered Stearns.
Semin Oncol, 2020 Jun 18; 47(4). PMID: 32546323    Free PMC article.
Review.
Sex Disparity Observed for Oncotype DX Breast Recurrence Score in Predicting Mortality Among Patients with Early Stage ER-Positive Breast Cancer.
Fei Wang, Sonya Reid, +6 authors, Xiao-Ou Shu.
Clin Cancer Res, 2019 Nov 22; 26(1). PMID: 31748278    Free PMC article.
Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26-30.
Jing Yu, Jiayi Wu, +6 authors, Kunwei Shen.
Oncol Lett, 2020 Jul 30; 20(2). PMID: 32724396    Free PMC article.
The healthcare value of the Magee Decision Algorithm™: use of Magee Equations™ and mitosis score to safely forgo molecular testing in breast cancer.
Rohit Bhargava, Beth Z Clark, +2 authors, David J Dabbs.
Mod Pathol, 2020 Mar 24; 33(8). PMID: 32203092    Free PMC article.
The 21-Gene Recurrence Score Assay and Prediction of Chemotherapy Benefit: A Propensity Score-Matched Analysis of the SEER Database.
In Sil Choi, Jiwoong Jung, +5 authors, Ki-Tae Hwang.
Cancers (Basel), 2020 Jul 12; 12(7). PMID: 32650374    Free PMC article.
Discordance in 21-gene recurrence scores between paired breast cancer samples is inversely associated with patient age.
Sarah M Bernhardt, Pallave Dasari, +6 authors, Wendy V Ingman.
Breast Cancer Res, 2020 Aug 20; 22(1). PMID: 32811558    Free PMC article.
Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients.
Yujie Lu, Yiwei Tong, +10 authors, Kunwei Shen.
Front Oncol, 2020 Aug 28; 10. PMID: 32850415    Free PMC article.
Association of sonographic features and molecular subtypes in predicting breast cancer disease outcomes.
Haoyu Wang, Jiejie Yao, +3 authors, Kunwei Shen.
Cancer Med, 2020 Jul 14; 9(17). PMID: 32657039    Free PMC article.
Mining Prognosis Index of Brain Metastases Using Artificial Intelligence.
Shigao Huang, Jie Yang, Simon Fong, Qi Zhao.
Cancers (Basel), 2019 Aug 10; 11(8). PMID: 31395825    Free PMC article.
Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer.
Mi Jeong Kwon, Jeong Eon Lee, +12 authors, Young Kee Shin.
Front Oncol, 2019 Aug 14; 9. PMID: 31404265    Free PMC article.
Endocrine Therapy in Early Breast Cancer.
Katja Krauss, Elmar Stickeler.
Breast Care (Basel), 2020 Sep 29; 15(4). PMID: 32982643    Free PMC article.
Review.
Genomic Signatures in Luminal Breast Cancer.
Julian Puppe, Tabea Seifert, +3 authors, Wolfram Malter.
Breast Care (Basel), 2020 Sep 29; 15(4). PMID: 32982645    Free PMC article.
Review.
The role of adjuvant chemotherapy in stage I-III male breast cancer: a SEER-based analysis.
Wei-Ping Li, Hong-Fei Gao, +8 authors, Kun Wang.
Ther Adv Med Oncol, 2020 Oct 06; 12. PMID: 33014148    Free PMC article.
Transcriptome-wide analysis and modelling of prognostic alternative splicing signatures in invasive breast cancer: a prospective clinical study.
Linbang Wang, Yuanyuan Wang, +8 authors, Jinxiang Tan.
Sci Rep, 2020 Oct 07; 10(1). PMID: 33020551    Free PMC article.
Clinical utility of genomic signatures in young breast cancer patients: a systematic review.
Cynthia Villarreal-Garza, Ana S Ferrigno, +3 authors, Hatem A Azim.
NPJ Breast Cancer, 2020 Oct 17; 6. PMID: 33062888    Free PMC article.
Review.
Question Prompt List to Support Patient-Provider Communication in the Use of the 21-Gene Recurrence Test: Feasibility, Acceptability, and Outcomes.
Jinani Jayasekera, Susan T Vadaparampil, +8 authors, Suzanne C O'Neill.
JCO Oncol Pract, 2020 May 29; 16(10). PMID: 32463763    Free PMC article.
Circulating MicroRNAs as Prognostic and Therapeutic Biomarkers in Breast Cancer Molecular Subtypes.
Veronica Zelli, Chiara Compagnoni, +7 authors, Edoardo Alesse.
J Pers Med, 2020 Aug 28; 10(3). PMID: 32842653    Free PMC article.
Review.
Integrated Multiparametric Radiomics and Informatics System for Characterizing Breast Tumor Characteristics with the OncotypeDX Gene Assay.
Michael A Jacobs, Christopher B Umbricht, +5 authors, Antonio C Wolff.
Cancers (Basel), 2020 Oct 01; 12(10). PMID: 32992569    Free PMC article.
Graphene Oxide-Template Gold Nanosheets as Highly Efficient Near-Infrared Hyperthermia Agents for Cancer Therapy.
Shuyi He, Jingyu Li, +5 authors, Xu Wu.
Int J Nanomedicine, 2020 Nov 06; 15. PMID: 33149586    Free PMC article.
Oncotype DX Breast Recurrence Score Distribution and Chemotherapy Benefit Among Women of Different Age Groups With HR-Positive, HER2-Negative, Node-Negative Breast Cancer in the SEER Database.
Ran Cheng, Xiangyi Kong, +2 authors, Jing Wang.
Front Oncol, 2020 Nov 17; 10. PMID: 33194568    Free PMC article.